What can our community do to support the global effort on COVID -19?
BIA webinar this Thursday 19 March.
This week the BIA will run a webinar discussing what can our community do to support the global effort on COVID -19?
Led by Steve Bates (CEO, BIA) the webinar will focus on:
- BIA activity so far to support the national and global effort
- BIA co-ordination touchpoints with government and others
- Key BIA workstreams
- Info and considerations for running a UK life science SME
- What do BIA members need at the moment?
- Possible future workstreams
Join us this Thursday at 11:30am for a look at the current situation.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Dr Jane Osbourn OBE
Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.
Jane is a scientific leader in the field of antibody engineering, and has made a significant contribution to the discovery and development of 8 marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and has served as Chair of the Board of Directors of the BioIndustry Association for the past four years. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.
Emma Du Four B.Sc. (Hons), MBA, FTOPRA
Emma Du Four is Head of International Regulatory Policy at AbbVie. She leads a team providing strategic guidance on key regulatory policy issues and external advocacy in support of access for patients to innovative medicines.
Emma has an honours degree in Biochemistry, a Masters degree in Business Administration and is a Fellow of the organisation for professionals in regulatory affairs. She partners with an extensive external network of industry, government, academic and healthcare system partners and has a broad range of experience across all aspects of innovative medicines development. Specific areas of expertise include regulatory policy & strategy development, clinical trials, biotechnology, real world evidence, pharmacovigilance and paediatric drug development.
Emma regularly represents AbbVie and industry more broadly on scientific and technical issues. She is Chair of the BioIndustry Association Regulatory Affairs Advisory Committee and Vice-Chair of the European Regulatory Expert Group. She has been influential in shaping the current global regulatory environment.
Ian McCubbin OBE
Chairing the Manufacturing Advisory Group for the Industrial Strategy Challenge Fund wave 1 as part of UKRI governance.
Active in the UK Advanced Therapy manufacturing community and working on interesting projects with interesting people
Previously lead the Advanced Therapies Manufacturing Task Force on behalf of the Medicines Manufacturing industry Partnership, which is an Industry body working with Government to anchor commercial scale manufacturing of Advanced Therapies in the UK, for the benefit of healthcare and the UK economy.
Dr Andy Richards CBE
Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Life-science, Biotechnology and Digital Health companies in the UK. He is currently Chairman of Congenica, Abcodia, Closed Loop Medicine, Arecor and the Babraham Research Campus and is a Director of Ieso Digital Health, Owlstone Medical, and Cancer Research Technology (the commercial board of CR-UK). He is an advisor to several investment funds, including Cambridge Innovation Capital and the UCL Technology Fund, and is Chair of the CRUK Seed Fund and a Director of the Scale-Up Institute.
Andy is a Cambridge Graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 30 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Andy is passionate about science and the translation of science to do good for society. The Life-sciences and Healthcare sectors provide the perfect arena for translating science into technology that can help people around the world. He received a CBE for services to investment in life-sciences in 2015.
The webinar is intended for BIA members but others are welcome to join us. This webinar is free-to-attend.